文献速递流行病学与生物统计临床试验与 GCP

血液透析滤过与血液透析治疗肾衰竭:随机对照试验的个体患者数据荟萃分析

Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials.
PubMed 文献 · Lancet · 2024-10-25

该个体患者数据荟萃分析纳入5项随机对照试验共4153例肾衰竭患者,比较在线血液透析滤过与血液透析对全因及病因特异性死亡率的影响。中位随访30个月,血液透析滤过组全因死亡477例(23.3%),血液透析组559例(27.0%),风险比0.84(95%CI 0.74-0.95)。对流转量呈剂量依赖性,对流体积越大死亡风险越低,各亚组间未见效应差异。

要点

  • 在线血液透析滤过较血液透析降低全因死亡风险,风险比0.84(95%CI 0.74-0.95)。
  • 对流体积与死亡风险呈梯度关系,对流体积增加,死亡风险降低。
  • 预设患者特征各亚组间未见效应差异。

核心结论

  • 与血液透析相比,在线血液透析滤过降低肾衰竭患者的全因死亡率。
  • 结果在不同患者与治疗特征间无差异,风险降低似乎呈剂量依赖性。
  • 作者认为该分析强化了血液透析滤过可被视为现行标准(即血液透析)的更优替代方案这一观点。

研究设计与样本

  • 个体患者数据荟萃分析,于2024年7月17日检索MEDLINE、Embase和Cochrane对照试验中心注册库,纳入自数据库建库以来发表、比较在线血液透析滤过与血液透析并设计用于测量死亡率结局的随机对照试验。
  • 共纳入5项试验,n=4153例患者,其中2070例接受血液透析、2083例接受血液透析滤过。
  • 主要结局为全因死亡率,采用Cox比例风险回归模型生成风险比及95%CI,基于预设患者特征进行亚组分析,并使用自然样条对对流转量进行剂量-反应分析。
  • 该分析已在PROSPERO注册(CRD42024511514)。

主要发现

  • 中位随访30个月(IQR 24-36)后,血液透析滤过组全因死亡477例(23.3%),血液透析组559例(27.0%),风险比0.84(95%CI 0.74-0.95)。
  • 各亚组间未见效应差异的证据。
  • 对流体积与死亡风险之间呈现梯度关系:随着体积增加,死亡风险降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-dose haemodiafiltration has been shown, in a randomised clinical trial, to result in a 23% lower risk of mortality for patients with kidney failure when compared with conventional high-flux haemodialysis. Nevertheless, whether treatment effects differ across subgroups, whether a dose-response relationship with convection volume exists, and the effects on cause-specific mortality remain unclear. The aim of this individual patient data meta-analysis was to compare the effects of haemodiafiltration and standard haemodialysis on all-cause and cause-specific mortality. METHODS: On July 17, 2024, we searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomised controlled trials, published from database inception, comparing online haemodiafiltration versus haemodialysis designed to measure mortality outcomes. The primary outcome was all-cause mortality. Hazard ratios were generated using Cox proportional hazards regression models reporting hazard ratios and 95% CIs. Subgroup analyses based on predefined patient characteristics and dose-response analyses using natural splines for convection volume were performed. This analysis is registered with PROSPERO (CRD42024511514). FINDINGS: Five trials (n=4153 patients; 2070 receiving haemodialysis and 2083 receiving haemodiafiltration) were eligible for inclusion in this analysis. After a median follow-up of 30 months (IQR 24-36), all-cause mortality occurred in 477 patients (23·3%) treated with haemodiafiltration compared with in 559 patients (27·0%) treated with haemodialysis (hazard ratio 0·84 [95% CI 0·74-0·95]). No evidence of a differential effect across subgroups was noted. A graded relationship between convection volume and mortality risk was apparent: as the volume increased, the mortality risk decreased. INTERPRETATION: Compared with haemodialysis, online haemodiafiltration reduces all-cause mortality in people with kidney failure. Results do not differ across patient and treatment characteristics and the risk reduction appears to be dose-dependent. In conclusion, the present analysis strengthens the notion that haemodiafiltration can be considered as a superior alternative to the present standard (ie, haemodialysis). FUNDING: European Commission Research and Innovation, Horizon 2020.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Vernooij RWM, Hockham C, Strippoli G, et al. Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials. Lancet. 2024. PMID: 39489903. doi:10.1016/S0140-6736(24)01859-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。